Amneal Pharmaceuticals (NASDAQ:AMRX) Trading Up 6.9% – Here’s What Happened

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) was up 6.9% during mid-day trading on Wednesday . The stock traded as high as $17.46 and last traded at $17.7980. 422,800 shares were traded during mid-day trading, a decline of 80% from the average session volume of 2,086,597 shares. The stock had previously closed at $16.65.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on AMRX shares. JPMorgan Chase & Co. restated an “overweight” rating and set a $22.00 price target on shares of Amneal Pharmaceuticals in a research report on Wednesday, August 26th. Wall Street Zen upgraded Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Sunday, July 12th. Barclays boosted their price objective on Amneal Pharmaceuticals from $15.00 to $16.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 20th. Leerink Partners started coverage on Amneal Pharmaceuticals in a research report on Wednesday, September 9th. They issued an “outperform” rating and a $23.00 target price on the stock. Finally, The Goldman Sachs Group reaffirmed a “buy” rating and issued a $21.00 price target on shares of Amneal Pharmaceuticals in a research note on Friday, July 31st. Eight research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $19.57.

Amneal Pharmaceuticals Stock Performance

The company has a market cap of $5.67 billion, a PE ratio of 36.32 and a beta of 1.24. The company has a debt-to-equity ratio of 77.65, a quick ratio of 1.44 and a current ratio of 2.20. The firm’s 50 day moving average is $17.76 and its 200-day moving average is $15.08.

Amneal Pharmaceuticals (NASDAQ:AMRX) last released its earnings results on Thursday, July 30th. The company reported $0.30 earnings per share for the quarter, topping analysts’ consensus estimates of $0.24 by $0.06. The business had revenue of $796.20 million for the quarter. Amneal Pharmaceuticals had a net margin of 5.05% and a negative return on equity of 584.46%. Amneal Pharmaceuticals has set its FY 2026 guidance at 0.960-1.060 EPS. On average, research analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.94 earnings per share for the current fiscal year.

Insider Activity at Amneal Pharmaceuticals

In related news, Director John Kiely sold 50,000 shares of Amneal Pharmaceuticals stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $17.64, for a total transaction of $882,000.00. Following the transaction, the director owned 210,252 shares in the company, valued at approximately $3,708,845.28. This trade represents a 19.21% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Nikita Shah sold 146,403 shares of the business’s stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $17.51, for a total value of $2,563,516.53. Following the transaction, the executive vice president directly owned 253,390 shares in the company, valued at $4,436,858.90. This trade represents a 36.62% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 413,016 shares of company stock valued at $7,216,567. 17.30% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Dimensional Fund Advisors LP raised its stake in Amneal Pharmaceuticals by 1.5% during the first quarter. Dimensional Fund Advisors LP now owns 5,690,586 shares of the company’s stock worth $70,723,000 after purchasing an additional 81,546 shares during the period. Allspring Global Investments Holdings LLC increased its holdings in shares of Amneal Pharmaceuticals by 72.2% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 2,549,572 shares of the company’s stock worth $32,405,000 after buying an additional 1,069,400 shares during the last quarter. Bank of New York Mellon Corp purchased a new stake in shares of Amneal Pharmaceuticals during the 2nd quarter valued at approximately $17,573,000. Penn Capital Management Company LLC acquired a new position in Amneal Pharmaceuticals in the fourth quarter valued at approximately $12,655,000. Finally, Principal Financial Group Inc. grew its position in Amneal Pharmaceuticals by 527.9% in the first quarter. Principal Financial Group Inc. now owns 972,529 shares of the company’s stock worth $12,089,000 after acquiring an additional 817,652 shares during the period. Institutional investors and hedge funds own 31.82% of the company’s stock.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and commercializes a broad portfolio of generic and specialty medicines. Its products include dosage forms such as tablets, capsules, injectables, ophthalmic products and inhalation therapies, with a focus on complex generics and other products that can be more difficult to develop or manufacture.

The company also markets branded specialty pharmaceuticals in areas including central nervous system disorders, endocrinology, metabolic disease and other therapeutic categories.